InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,558.60
(
0.90%
)
US TECH 100
19,812.40
(
0.87%
)
Dow Jones
39,268.81
(
-0.10%
)
Brent Oil
86.81
(
-0.60%
)
Bitcoin
56,740.37
(
-0.42%
)
Post# of 252491
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119981
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 195232

Monday, 09/28/2015 10:57:34 AM

Monday, September 28, 2015 10:57:34 AM

Post# of 252491
SNY, LLY settle litigation wrt LLY’s Lantus FoB, called Basaglar:

http://finance.yahoo.com/news/lilly-sanofi-reach-settlement-agreement-133300869.html

Eli Lilly and Company has entered into a settlement agreement to resolve patent litigation with Sanofi regarding its insulin glargine product, Basaglar.

As a part of the agreement, Lilly and its alliance partner, Boehringer Ingelheim, will have the ability to launch Basaglar in the U.S. on December 15, 2016. Under the terms of the agreement, Sanofi has granted Lilly a royalty-bearing license so Lilly can manufacture and sell Basaglar in the Kwikpen device globally. Further details regarding the settlement are confidential.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up